Cargando…
Signaling Pathways mTOR and ERK as Therapeutic Targets in Sinonasal Intestinal-Type Adenocarcinoma
Despite advances in surgery and radiotherapy, the overall prognosis of sinonasal intestinal-type adenocarcinoma (ITAC) is poor, and new treatment options are needed. Recent studies have indicated alterations in cellular signaling pathways that may serve as targets for modern inhibitors. Our aim was...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606341/ https://www.ncbi.nlm.nih.gov/pubmed/37894790 http://dx.doi.org/10.3390/ijms242015110 |
_version_ | 1785127293140598784 |
---|---|
author | Codina-Martínez, Helena Lorenzo-Guerra, Sara Lucila Cabal, Virginia N. García-Marín, Rocío Suárez-Fernández, Laura Vivanco, Blanca Sánchez-Fernández, Paula López, Fernando Llorente, José Luis Hermsen, Mario A. |
author_facet | Codina-Martínez, Helena Lorenzo-Guerra, Sara Lucila Cabal, Virginia N. García-Marín, Rocío Suárez-Fernández, Laura Vivanco, Blanca Sánchez-Fernández, Paula López, Fernando Llorente, José Luis Hermsen, Mario A. |
author_sort | Codina-Martínez, Helena |
collection | PubMed |
description | Despite advances in surgery and radiotherapy, the overall prognosis of sinonasal intestinal-type adenocarcinoma (ITAC) is poor, and new treatment options are needed. Recent studies have indicated alterations in cellular signaling pathways that may serve as targets for modern inhibitors. Our aim was to evaluate the frequency of mTOR and ERK pathway upregulation in a retrospective series of 139 ITAC and to test the efficacy and mechanism of action of candidate targeted inhibitors in cell line ITAC-3. An immunohistochemical analysis on p-AKT, p-mTOR, p-S6, p-4E-BP1, and p-ERK indicated, respectively, a 68% and 57% mTOR and ERK pathway activation. In vitro studies using low doses of mTOR inhibitor everolimus and ERK inhibitor selumetinib showed significant growth inhibition as monotherapy and especially as combined therapy. This effect was accompanied by the downregulation of mTOR and ERK protein expression. Our data open a new and promising possibility for personalized treatment of ITAC patients. |
format | Online Article Text |
id | pubmed-10606341 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106063412023-10-28 Signaling Pathways mTOR and ERK as Therapeutic Targets in Sinonasal Intestinal-Type Adenocarcinoma Codina-Martínez, Helena Lorenzo-Guerra, Sara Lucila Cabal, Virginia N. García-Marín, Rocío Suárez-Fernández, Laura Vivanco, Blanca Sánchez-Fernández, Paula López, Fernando Llorente, José Luis Hermsen, Mario A. Int J Mol Sci Article Despite advances in surgery and radiotherapy, the overall prognosis of sinonasal intestinal-type adenocarcinoma (ITAC) is poor, and new treatment options are needed. Recent studies have indicated alterations in cellular signaling pathways that may serve as targets for modern inhibitors. Our aim was to evaluate the frequency of mTOR and ERK pathway upregulation in a retrospective series of 139 ITAC and to test the efficacy and mechanism of action of candidate targeted inhibitors in cell line ITAC-3. An immunohistochemical analysis on p-AKT, p-mTOR, p-S6, p-4E-BP1, and p-ERK indicated, respectively, a 68% and 57% mTOR and ERK pathway activation. In vitro studies using low doses of mTOR inhibitor everolimus and ERK inhibitor selumetinib showed significant growth inhibition as monotherapy and especially as combined therapy. This effect was accompanied by the downregulation of mTOR and ERK protein expression. Our data open a new and promising possibility for personalized treatment of ITAC patients. MDPI 2023-10-12 /pmc/articles/PMC10606341/ /pubmed/37894790 http://dx.doi.org/10.3390/ijms242015110 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Codina-Martínez, Helena Lorenzo-Guerra, Sara Lucila Cabal, Virginia N. García-Marín, Rocío Suárez-Fernández, Laura Vivanco, Blanca Sánchez-Fernández, Paula López, Fernando Llorente, José Luis Hermsen, Mario A. Signaling Pathways mTOR and ERK as Therapeutic Targets in Sinonasal Intestinal-Type Adenocarcinoma |
title | Signaling Pathways mTOR and ERK as Therapeutic Targets in Sinonasal Intestinal-Type Adenocarcinoma |
title_full | Signaling Pathways mTOR and ERK as Therapeutic Targets in Sinonasal Intestinal-Type Adenocarcinoma |
title_fullStr | Signaling Pathways mTOR and ERK as Therapeutic Targets in Sinonasal Intestinal-Type Adenocarcinoma |
title_full_unstemmed | Signaling Pathways mTOR and ERK as Therapeutic Targets in Sinonasal Intestinal-Type Adenocarcinoma |
title_short | Signaling Pathways mTOR and ERK as Therapeutic Targets in Sinonasal Intestinal-Type Adenocarcinoma |
title_sort | signaling pathways mtor and erk as therapeutic targets in sinonasal intestinal-type adenocarcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606341/ https://www.ncbi.nlm.nih.gov/pubmed/37894790 http://dx.doi.org/10.3390/ijms242015110 |
work_keys_str_mv | AT codinamartinezhelena signalingpathwaysmtoranderkastherapeutictargetsinsinonasalintestinaltypeadenocarcinoma AT lorenzoguerrasaralucila signalingpathwaysmtoranderkastherapeutictargetsinsinonasalintestinaltypeadenocarcinoma AT cabalvirginian signalingpathwaysmtoranderkastherapeutictargetsinsinonasalintestinaltypeadenocarcinoma AT garciamarinrocio signalingpathwaysmtoranderkastherapeutictargetsinsinonasalintestinaltypeadenocarcinoma AT suarezfernandezlaura signalingpathwaysmtoranderkastherapeutictargetsinsinonasalintestinaltypeadenocarcinoma AT vivancoblanca signalingpathwaysmtoranderkastherapeutictargetsinsinonasalintestinaltypeadenocarcinoma AT sanchezfernandezpaula signalingpathwaysmtoranderkastherapeutictargetsinsinonasalintestinaltypeadenocarcinoma AT lopezfernando signalingpathwaysmtoranderkastherapeutictargetsinsinonasalintestinaltypeadenocarcinoma AT llorentejoseluis signalingpathwaysmtoranderkastherapeutictargetsinsinonasalintestinaltypeadenocarcinoma AT hermsenmarioa signalingpathwaysmtoranderkastherapeutictargetsinsinonasalintestinaltypeadenocarcinoma |